Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGB | P11216 | 8/20 | 0.45 |
| ▸ | PYGL | P06737 | 3/20 | 0.37 |
| ▸ | PYGM | P11217 | 2/20 | 0.37 |
| ▸ | GBA1 | P04062 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | UMPS | P11172 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5676433 | 0.94 | PYGB (0.51) | PYGBPYGLPYGMGBA1LMNA | |
| SCHEMBL28495873 | 0.94 | PYGB (0.51) | PYGBPYGLPYGMGBA1LMNA | |
| SCHEMBL28775128 | 0.94 | PYGB (0.51) | PYGBPYGLPYGMGBA1LMNA | |
| SCHEMBL4224352 | 0.84 | PYGB (0.39) | PYGBPYGLPYGMGBA1LMNA | |
| SCHEMBL7074366 | 0.84 | PYGB (0.39) | PYGBPYGLPYGMGBA1LMNA | |
| SCHEMBL7107462 | 0.84 | PYGB (0.39) | PYGBPYGLPYGMGBA1LMNA | |
| SCHEMBL10408121 | 0.84 | PYGB (0.39) | PYGBPYGLPYGMGBA1LMNA | |
| SCHEMBL7074369 | 0.84 | PYGB (0.39) | PYGBPYGLPYGMGBA1LMNA | |
| SCHEMBL4602205 | 0.84 | PYGB (0.39) | PYGBPYGLPYGMGBA1LMNA | |
| SCHEMBL824879 | 0.84 | PYGB (0.39) | PYGBPYGLPYGMGBA1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101437829-B | Bisadenosine compounds as adenosine A2A receptor agonists | NOVARTIS AG | 2012-03-21 | — | — | CN | disclosed |
| CN-101437829-A | Bisadenosine compounds as adenosine A2A receptor agonists | NOVARTIS AG (CH) | 2009-05-20 | — | — | CN | disclosed |